Integrated Management Strategies for Epidermolysis Bullosa: Current Insights [Corrigendum]

This article refers to:

Integrated Management Strategies for Epidermolysis Bullosa: Current Insights

Sait H, Srivastava S, Saxena D. Int J Gen Med. 2022;15:5133–5144.

The authors have advised that the Figures were labelled incorrectly and Figure 1 should appear in the paper as Figure 2 and vice versa.

Page 5134, Figure 1, the correct figure is as follows.

Figure 1 The 4 layers of skin with dermo-epidermal junctions and corresponding genes involved in the maintenance of their integrity. Basal keratinocytes secrete KRT5 and KRT14, which form the intermediate filaments and interact with other cytoskeletal proteins in epidermis and lamina lucida to provide integrity and adhesion. Gain of function mutations in KLHL24 gene leads to breakdown of intermediate filaments.

Page 5137, Figure 2, the correct figure is as follows.

Figure 2 Various novel therapeutic strategies that are being explored in management of epidermolysis bullosa.

Abbreviations: AON, Anti sense oligonucleotide; SMaRT, Spliceosome-mediated RNA trans-splicing.

The authors apologize for the error.